completed2022-04-01D series

Anifrolumab

Systemischer Lupus erythematodes

Open official case page ↗

Brand: Saphnelo
Manufacturer: AstraZeneca GmbH

G-BA action

final resolution

2023-03-28

Arzneimittel-Richtlinie/Anlage XII: Anifrolumab (systemischer Lupus erythematodes) – Therapiekosten

Evidence-checked summary

The G-BA issued a final resolution on 2023-03-28. The official page states that it took effect as follows: 30.03.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.

Open G-BA decision →Open official action source ↗

Final benefit result

G-BA result by patient group

Open decision 5646 →

Patient group

Erwachsene mit moderatem bis schwerem, aktivem Autoantikörper-positivem systemischem Lupus erythematodes (SLE), die bereits eine Standardtherapie erhalten

Added benefit not proven

Comparator
Belimumab

Open official result PDF ↗

Official case record

What happened, in source order

No inferred stages

Consultation record

Oral hearing and Wortprotokoll

1 hearing

2022-08-08

48 parsed turns

Oral hearing: Anifrolumab (Systemischer Lupus erythematodes)

Official Wortprotokoll · 10 pages

Open official source PDF ↗Read transcript turns →

IQWiG comparison

Assessment record versus G-BA action

1 reference

IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.

A22-35

matched

Anifrolumab (systemischer Lupus erythematodes) – Nutzenbewertung gemäß § 35a SGB V

Official assessment PDF · 64 pages

Open structured assessment →Open official PDF ↗

G-BA decisions

Distinct actions and documents

3 decision

2022-10-06

final resolution

Arzneimittel-Richtlinie/Anlage XII: Anifrolumab (Systemischer Lupus erythematodes)

The G-BA found no proven added benefit for Erwachsene mit moderatem bis schwerem, aktivem Autoantikörper-positivem systemischem Lupus erythematodes (SLE), die bereits eine Standardtherapie erhalten. The appropriate comparator was Belimumab. The G-BA issued a final resolution on 2022-10-06. The official page states that it took effect as follows: 06.10.2022. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

3 official documents · 4 cited claims

Open decision →

2022-12-20

final resolution

Arzneimittel-Richtlinie/Anlage XII: Anifrolumab (systemischer Lupus erythematodes) – Therapiekosten

The G-BA issued a final resolution on 2022-12-20. The official page states that it took effect as follows: 22.12.2022. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

2 official documents · 3 cited claims

Open decision →

2023-03-28

final resolution